Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Ras has long been viewed as a promising target for cancer therapy. Farnesylthiosalicylic acid (FTS), as the only Ras inhibitor has ever entered phase II clinical trials, has yielded disappointing results due to its strong hydrophobicity, poor tumor-targeting capacity, and low therapeutic efficiency. Thus, enhancing hydrophilicity and tumor-targeting capacity of FTS for improving its therapeutic efficacy is of great significance. In this study we conjugated FTS with a cancer-targeting small molecule dye IR783 and characterized the anticancer properties of the conjugate FTS-IR783. We showed that IR783 conjugation greatly improved the hydrophilicity, tumor-targeting and therapeutic potential of FTS. After a single oral administration in Balb/c mice, the relative bioavailability of FTS-IR783 was increased by 90.7% compared with FTS. We demonstrated that organic anion transporting polypeptide (OATP) and endocytosis synergistically drove the uptake of the FTS-IR783 conjugate in breast cancer MDA-MB-231 cells, resulting in superior tumor-targeting ability of the conjugate both in vitro and in vivo. We further revealed that FTS-IR783 conjugate could bind with and directly activate AMPK rather than affecting Ras, and subsequently regulate the TSC2/mTOR signaling pathway, thus achieving 2–10-fold increased anti-cancer therapeutic efficacy against 6 human breast cancer cell lines compared to FTS both in vivo and in vitro. Overall, our data highlights a promising approach for the modification of the anti-tumor drug FTS using IR783 and makes it possible to return FTS back to the clinic with a better efficacy. [Figure not available: see fulltext.]

References Powered by Scopus

Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay

1496Citations
N/AReaders
Get full text

Strategies to address low drug solubility in discovery and development

1322Citations
N/AReaders
Get full text

Lipophilicity in drug discovery

704Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy

42Citations
N/AReaders
Get full text

Delivery of Small-Molecule Drugs and Protein Drugs by Injectable Acid-Responsive Self-Assembled COF Hydrogels for Combinatorial Lung Cancer Treatment

11Citations
N/AReaders
Get full text

Structure-Inherent Tumor-Targeted IR-783 for Near-Infrared Fluorescence-Guided Photothermal Therapy

2Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Huang, Q. ju, Liao, G. chao, Zhuang, X. rong, Yang, M. lan, Yao, J. jing, Deng, J. hua, … Lu, L. lin. (2022). Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice. Acta Pharmacologica Sinica, 43(7), 1843–1856. https://doi.org/10.1038/s41401-021-00775-5

Readers' Seniority

Tooltip

Lecturer / Post doc 1

50%

PhD / Post grad / Masters / Doc 1

50%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 1

33%

Computer Science 1

33%

Chemistry 1

33%

Save time finding and organizing research with Mendeley

Sign up for free